365 related articles for article (PubMed ID: 19147570)
1. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition.
Mirzoeva OK; Das D; Heiser LM; Bhattacharya S; Siwak D; Gendelman R; Bayani N; Wang NJ; Neve RM; Guan Y; Hu Z; Knight Z; Feiler HS; Gascard P; Parvin B; Spellman PT; Shokat KM; Wyrobek AJ; Bissell MJ; McCormick F; Kuo WL; Mills GB; Gray JW; Korn WM
Cancer Res; 2009 Jan; 69(2):565-72. PubMed ID: 19147570
[TBL] [Abstract][Full Text] [Related]
2. PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells.
Aksamitiene E; Kholodenko BN; Kolch W; Hoek JB; Kiyatkin A
Cell Signal; 2010 Sep; 22(9):1369-78. PubMed ID: 20471474
[TBL] [Abstract][Full Text] [Related]
3. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
[TBL] [Abstract][Full Text] [Related]
4. Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells.
Yuen HF; Abramczyk O; Montgomery G; Chan KK; Huang YH; Sasazuki T; Shirasawa S; Gopesh S; Chan KW; Fennell D; Janne P; El-Tanani M; Murray JT
Biosci Rep; 2012 Aug; 32(4):413-22. PubMed ID: 22668349
[TBL] [Abstract][Full Text] [Related]
5. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells.
Bachleitner-Hofmann T; Sun MY; Chen CT; Tang L; Song L; Zeng Z; Shah M; Christensen JG; Rosen N; Solit DB; Weiser MR
Mol Cancer Ther; 2008 Nov; 7(11):3499-508. PubMed ID: 18974395
[TBL] [Abstract][Full Text] [Related]
6. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.
Khalili JS; Yu X; Wang J; Hayes BC; Davies MA; Lizee G; Esmaeli B; Woodman SE
Clin Cancer Res; 2012 Aug; 18(16):4345-55. PubMed ID: 22733540
[TBL] [Abstract][Full Text] [Related]
7. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.
Carlino MS; Todd JR; Gowrishankar K; Mijatov B; Pupo GM; Fung C; Snoyman S; Hersey P; Long GV; Kefford RF; Rizos H
Mol Oncol; 2014 May; 8(3):544-54. PubMed ID: 24476679
[TBL] [Abstract][Full Text] [Related]
8. Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer.
Naderi A; Chia KM; Liu J
Breast Cancer Res; 2011 Apr; 13(2):R36. PubMed ID: 21457548
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells.
Yi YW; Hong W; Kang HJ; Kim HJ; Zhao W; Wang A; Seong YS; Bae I
J Cell Mol Med; 2013 May; 17(5):648-56. PubMed ID: 23601074
[TBL] [Abstract][Full Text] [Related]
10. Leptin stimulates ovarian cancer cell growth and inhibits apoptosis by increasing cyclin D1 and Mcl-1 expression via the activation of the MEK/ERK1/2 and PI3K/Akt signaling pathways.
Chen C; Chang YC; Lan MS; Breslin M
Int J Oncol; 2013 Mar; 42(3):1113-9. PubMed ID: 23354006
[TBL] [Abstract][Full Text] [Related]
11. PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1.
Ebi H; Costa C; Faber AC; Nishtala M; Kotani H; Juric D; Della Pelle P; Song Y; Yano S; Mino-Kenudson M; Benes CH; Engelman JA
Proc Natl Acad Sci U S A; 2013 Dec; 110(52):21124-9. PubMed ID: 24327733
[TBL] [Abstract][Full Text] [Related]
12. Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells.
Shingu T; Holmes L; Henry V; Wang Q; Latha K; Gururaj AE; Gibson LA; Doucette T; Lang FF; Rao G; Yuan L; Sulman EP; Farrell NP; Priebe W; Hess KR; Wang YA; Hu J; Bögler O
J Transl Med; 2016 Feb; 14():46. PubMed ID: 26861698
[TBL] [Abstract][Full Text] [Related]
13. MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK-mediated HER2 phosphorylation at Thr701.
Chen CH; Hsia TC; Yeh MH; Chen TW; Chen YJ; Chen JT; Wei YL; Tu CY; Huang WC
Mol Oncol; 2017 Sep; 11(9):1273-1287. PubMed ID: 28632938
[TBL] [Abstract][Full Text] [Related]
14. Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs.
Steelman LS; Abrams SL; Shelton JG; Chappell WH; Bäsecke J; Stivala F; Donia M; Nicoletti F; Libra M; Martelli AM; McCubrey JA
Cell Cycle; 2010 Apr; 9(8):1629-38. PubMed ID: 20372086
[TBL] [Abstract][Full Text] [Related]
15. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
16. Ursodeoxycholic acid shows antineoplastic effects in bile duct cancer cells via apoptosis induction; p53 activation; and EGFR-ERK, COX-2, and PI3K-AKT pathway inhibition.
Lee J; Hong EM; Kim JH; Kim JH; Jung JH; Park SW; Koh DH; Jang HJ
Mol Biol Rep; 2021 Sep; 48(9):6231-6240. PubMed ID: 34392440
[TBL] [Abstract][Full Text] [Related]
17. MEK-ERK pathway modulation ameliorates pulmonary fibrosis associated with epidermal growth factor receptor activation.
Madala SK; Schmidt S; Davidson C; Ikegami M; Wert S; Hardie WD
Am J Respir Cell Mol Biol; 2012 Mar; 46(3):380-8. PubMed ID: 22021337
[TBL] [Abstract][Full Text] [Related]
18. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
Van Swearingen AED; Sambade MJ; Siegel MB; Sud S; McNeill RS; Bevill SM; Chen X; Bash RE; Mounsey L; Golitz BT; Santos C; Deal A; Parker JS; Rashid N; Miller CR; Johnson GL; Anders CK
Neuro Oncol; 2017 Oct; 19(11):1481-1493. PubMed ID: 28486691
[TBL] [Abstract][Full Text] [Related]
19. PI3K-FRAP/mTOR pathway is critical for hepatocyte proliferation whereas MEK/ERK supports both proliferation and survival.
Coutant A; Rescan C; Gilot D; Loyer P; Guguen-Guillouzo C; Baffet G
Hepatology; 2002 Nov; 36(5):1079-88. PubMed ID: 12395317
[TBL] [Abstract][Full Text] [Related]
20. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.
Soares HP; Ming M; Mellon M; Young SH; Han L; Sinnet-Smith J; Rozengurt E
Mol Cancer Ther; 2015 Apr; 14(4):1014-23. PubMed ID: 25673820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]